|
1
|
Ostrom QT, Gittleman H, Liao P, Rouse C,
Chen Y, Dowling J, Wolinsky Y, Kruchko C and Barnholtz-Sloan J:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2007–2011. Neuro Oncol.
16(Suppl 4): iv1–iv63. 2014. View Article : Google Scholar :
|
|
2
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ohgaki H and Kleihues P: Population-based
studies on incidence, survival rates, and genetic alterations in
astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol.
64:479–489. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arora RS, Alston RD, Eden TO, Estlin EJ,
Moran A and Birch JM: Age-incidence patterns of primary CNS tumors
in children, adolescents, and adults in England. Neuro Oncol.
11:403–413. 2009. View Article : Google Scholar :
|
|
5
|
Lee CH, Jung KW, Yoo H, Park S and Lee SH:
Epidemiology of primary brain and central nervous system tumors in
Korea. J Korean Neurosurg Soc. 48:145–152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dobes M, Khurana VG, Shadbolt B, Jain S,
Smith SF, Smee R, Dexter M and Cook R: Increasing incidence of
glioblastoma multiforme and meningioma, and decreasing incidence of
Schwannoma (2000–2008): Findings of a multicenter Australian study.
Surg Neurol Int. 2:1762011. View Article : Google Scholar
|
|
7
|
Gigineishvili D, Shengelia N, Shalashvili
G, Rohrmann S, Tsiskaridze A and Shakarishvili R: Primary brain
tumour epidemiology in Georgia: First-year results of a
population-based study. J Neurooncol. 112:241–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dunn GP, Rinne ML, Wykosky J, Genovese G,
Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, et
al: Emerging insights into the molecular and cellular basis of
glioblastoma. Genes Dev. 26:756–784. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Husain SR, Kreitman RJ, Pastan I and Puri
RK: Interleukin-4 receptor-directed cytotoxin therapy of
AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat
Med. 5:817–822. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Joshi BH, Leland P, Asher A, Prayson RA,
Varricchio F and Puri RK: In situ expression of interleukin-4
(IL-4) receptors in human brain tumors and cytotoxicity of a
recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.
Cancer Res. 61:8058–8061. 2001.PubMed/NCBI
|
|
13
|
Joshi BH, Leland P, Lababidi S, Varrichio
F and Puri RK: Interleukin-4 receptor alpha overexpression in human
bladder cancer correlates with the pathological grade and stage of
the disease. Cancer Med. 3:1615–1628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shimamura T, Royal RE, Kioi M, Nakajima A,
Husain SR and Puri RK: Interleukin-4 cytotoxin therapy synergizes
with gemcitabine in a mouse model of pancreatic ductal
adenocarcinoma. Cancer Res. 67:9903–9912. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Husain SR, Gill P, Kreitman RJ, Pastan I
and Puri RK: Interleukin-4 receptor expression on AIDS-associated
Kaposi's sarcoma cells and their targeting by a chimeric protein
comprised of circularly permuted interleukin-4 and Pseudomonas
exotoxin. Mol Med. 3:327–338. 1997.PubMed/NCBI
|
|
16
|
Kawakami K, Leland P and Puri RK:
Structure, function, and targeting of interleukin 4 receptors on
human head and neck cancer cells. Cancer Res. 60:2981–2987.
2000.PubMed/NCBI
|
|
17
|
Murata T, Taguchi J and Puri RK:
Interleukin-13 receptor alpha' but not alpha chain: A functional
component of interleukin-4 receptors. Blood. 91:3884–3891.
1998.PubMed/NCBI
|
|
18
|
Hosoyama T, Aslam MI, Abraham J, Prajapati
SI, Nishijo K, Michalek JE, Zarzabal LA, Nelon LD, Guttridge DC,
Rubin BP, et al: IL-4R drives dedifferentiation, mitogenesis, and
metastasis in rhabdomyosarcoma. Clin Cancer Res. 17:2757–2766.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kohno M, Horibe T, Haramoto M, Yano Y,
Ohara K, Nakajima O, Matsuzaki K and Kawakami K: A novel hybrid
peptide targeting EGFR-expressing cancers. Eur J Cancer.
47:773–783. 2011. View Article : Google Scholar
|
|
20
|
Garland L, Gitlitz B, Ebbinghaus S, Pan H,
de Haan H, Puri RK, Von Hoff D and Figlin R: Phase I trial of
intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in
patients with advanced solid tumors that express the IL-4 receptor.
J Immunother. 28:376–381. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoon YI, Kwon YS, Cho HS, Heo SH, Park KS,
Park SG, Lee SH, Hwang SI, Kim YI, Jae HJ, et al:
Ultrasound-mediated gene and drug delivery using a
microbubble-liposome particle system. Theranostics. 4:1133–1144.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sarangthem V, Cho EA, Bae SM, Singh TD,
Kim SJ, Kim S, Jeon WB, Lee BH and Park RW: Construction and
application of elastin like polypeptide containing IL-4 receptor
targeting peptide. PLoS One. 8:e818912013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Serwer LP and James CD: Challenges in drug
delivery to tumors of the central nervous system: An overview of
pharmacological and surgical considerations. Adv Drug Deliv Rev.
64:590–597. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao H and Jiang X: Progress on the
diagnosis and evaluation of brain tumors. Cancer Imaging.
13:466–481. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao H, Pang Z and Jiang X: Targeted
delivery of nano-therapeutics for major disorders of the central
nervous system. Pharm Res. 30:2485–2498. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhan C, Wei X, Qian J, Feng L, Zhu J and
Lu W: Co-delivery of TRAIL gene enhances the anti-glioblastoma
effect of paclitaxel in vitro and in vivo. J Control Release.
160:630–636. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sarin H, Kanevsky AS, Wu H, Sousa AA,
Wilson CM, Aronova MA, Griffiths GL, Leapman RD and Vo HQ:
Physiologic upper limit of pore size in the blood-tumor barrier of
malignant solid tumors. J Transl Med. 7:512009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Groothuis DR: The blood-brain and
blood-tumor barriers: A review of strategies for increasing drug
delivery. Neuro Oncol. 2:45–59. 2000.
|
|
29
|
Papademetriou IT and Porter T: Promising
approaches to circumvent the blood-brain barrier: Progress,
pitfalls and clinical prospects in brain cancer. Ther Deliv.
6:989–1016. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wei X, Gao J, Zhan C, Xie C, Chai Z, Ran
D, Ying M, Zheng P and Lu W: Liposome-based glioma targeted drug
delivery enabled by stable peptide ligands. J Control Release.
218:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
